Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. septic shock
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Downloads

Refine by
Date

  • Older

Septic Shock Articles & Analysis

14 news found

Biocartis Announces Presentation of Three Idyllaâ„¢ Studies at 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)

Biocartis Announces Presentation of Three Idyllaâ„¢ Studies at 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)

Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that three Idylla™ study posters, of which two on the SeptiCyte® RAPID (developed in collaboration with Immunexpress) and one on the Idylla™ SARS-CoV-2 Test (CE-IVD) and Idylla™ SARS-CoV-2/Flu/RSV Panel (CE-IVD), ...

ByBiocartis NV


SafeHeal Announces Successful Launch of IDE Study for Colovac Endoluminal Bypass Sheath

SafeHeal Announces Successful Launch of IDE Study for Colovac Endoluminal Bypass Sheath

Paris, France, & Guilford, CT – April 1, 2022 – SafeHeal™, a leading innovator in the field of digestive surgery, recently announced the first patient enrollment in its pivotal study of Colovac™, a groundbreaking endoluminal bypass sheath. Colovac is intended as an alternative to temporary diverting ostomy for patients undergoing colorectal resection. Up to 20 U.S. ...

BySafeHeal


Daxor Announces Key Milestones Achieved for Multicenter BVA-100 Study in Hospitalized Patients With COVID-19

Daxor Announces Key Milestones Achieved for Multicenter BVA-100 Study in Hospitalized Patients With COVID-19

Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces patient enrollment is complete and data analysis is underway in preparation for publication of the multi-center observational prospective study utilizing Daxor’s BVA-100 (Blood Volume Analyzer, “BVA”) technology in hospitalized COVID-19 patients. NYU Langone Health, Wake ...

ByDaxor Corporation


Daxor Announces Key Milestones Achieved for Multicenter Bva-100® Study In Hospitalized Patients With Covid-19

Daxor Announces Key Milestones Achieved for Multicenter Bva-100® Study In Hospitalized Patients With Covid-19

Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces patient enrollment is complete and data analysis is underway in preparation for publication of the multi-center observational prospective study utilizing Daxor’s BVA-100 (Blood Volume Analyzer, “BVA”) technology in hospitalized COVID-19 patients. NYU Langone Health, Wake ...

ByDaxor Corporation


Imbed Biosciences Wins a $2M Award From the U.S. Army to Prevent Combat Wound Infections

Imbed Biosciences Wins a $2M Award From the U.S. Army to Prevent Combat Wound Infections

Imbed Biosciences, Inc. announced today that it has been awarded a contract for $1,999,481 by the U.S. Army Medical Research and Development Command’s (USAMRDC) Military Infectious Diseases Research Program (MIDRP) to accelerate clinical development of an antibiofilm version of its next-generation Microlyte® Matrix wound dressing that can kill bacteria hidden in biofilms. The contract ...

ByImbed Biosciences


New Research Demonstrates Clinical Utility of Daxor Corporation Blood Volume (BVA-100) Diagnostic in Neurocritical Care

New Research Demonstrates Clinical Utility of Daxor Corporation Blood Volume (BVA-100) Diagnostic in Neurocritical Care

Data Highlight Daxor’s Diagnostic Changes Care in 69% of Patients With Non-Traumatic Subarachnoid Hemorrhage (nSAH) Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces new data demonstrating the clinical utility of the BVA-100 blood test in patients with non-traumatic subarachnoid hemorrhage (nSAH) presented at the virtual ...

ByDaxor Corporation


Cytovale Begins Enrollment in FDA 510(k) Clinical Validation Study of IntelliSep Rapid Sepsis Test

Cytovale Begins Enrollment in FDA 510(k) Clinical Validation Study of IntelliSep Rapid Sepsis Test

Cytovale, a medical diagnostics company focused on providing a faster, more insightful way to diagnose fast-moving and immune-mediated diseases, today announced the first enrollment in a clinical trial of the Cytovale system and IntelliSep test to aid in the rapid assessment of potential for sepsis in the emergency department (ED). The trial, A Clinical Validation Solving the Question of ...

ByCytovale Inc.


Cytovale Receives Distinguished Abstract Award from AACC for Evaluation of Sepsis Assay

Cytovale Receives Distinguished Abstract Award from AACC for Evaluation of Sepsis Assay

Cytovale, Inc., a medical technology company dedicated to revolutionizing diagnostics using cell mechanics and machine learning, has received an AACC Academy’s Distinguished Abstract Award for its abstract titled “Rapidly Assessing the Host Immune Response for the Diagnosis of Sepsis, a Prospective Multi-Site Clinical Study in the Emergency Department (ED) Employing the Leukocyte ...

ByCytovale Inc.


New respiratory multitest

New respiratory multitest

The new Vitassay SARS-CoV-2 + Flu A + B + RSV + Adeno Resp. is a rapid, immunochromatographic assay for the simultaneous qualitative detection of nucleoprotein antigen of SARS-CoV-2, Influenza type A, Influenza type B, RSV and Adenovirus from nasopharyngeal swabs samples from patients suspected of COVID-19 infection and/or Influenza A and/or Influenza B and/or Respiratory Syncytial Virus (RSV) ...

ByVitassay Healthcare, S.L.U.


Thermo Fisher Scientific Supports Sepsis Awareness Month in September

Thermo Fisher Scientific Supports Sepsis Awareness Month in September

Thermo Fisher Scientific Inc., the world leader in serving science, announces its support of Sepsis Awareness Month to drive awareness around sepsis, a complex clinical syndrome and a leading cause of death globally.1 Throughout the month of September, supporters are encouraged to join together to raise sepsis awareness through posting on social media, handing out brochures or stickers, giving ...

ByThermo Fisher Scientific, LIMS & Laboratory Software


SafeHeal obtains CE-mark for Colovac, its novel endoluminal bypass sheath

SafeHeal obtains CE-mark for Colovac, its novel endoluminal bypass sheath

Paris, France, April 3, 2019 – SafeHeal, a leading innovator in the field of digestive surgery, announces today that its unique Colovac bypass sheath has received the CE-mark. Colovac is a unique endoluminal bypass sheath placed in the colon following colorectal resection. It suppresses the contact of fecal content with the colorectal anastomotic site in order to significantly improve ...

BySafeHeal


SafeHeal Completes First-in-Human Clinical Study of Endoluminal Bypass Sheath

SafeHeal Completes First-in-Human Clinical Study of Endoluminal Bypass Sheath

Jan 11, 2019 –SafeHeal, an innovator in the field of digestive surgery, has concluded its first-in-human clinical study for its novel Colovac bypass sheath in patients undergoing colorectal surgery. The single-arm 15-patient study was aimed at evaluating the safety and efficacy of Colovac in the protection of colorectal anastomosis in adult patients who were scheduled to ...

BySafeHeal


Abionic Successfully Raises CHF20 Million in Series C Financing

Abionic Successfully Raises CHF20 Million in Series C Financing

Abionic SA, a developer of disruptive nanotechnology based rapid diagnostic solutions, announced today the successful closing of a CHF20 million Series C financing. The round was led by Pierangelo Bottinelli, Chairman of Symphony International Holdings Limited, and included Philippe Glatz (Chairman of two private hospitals), Peter Brabeck-Letmathe (former CEO and Chairman of Nestlé), ...

ByAbionic SA


SAFEHEAL starts first-in-human and CE-mark clinical study of endoluminal bypass sheath with the potential of replacing ostomy

SAFEHEAL starts first-in-human and CE-mark clinical study of endoluminal bypass sheath with the potential of replacing ostomy

Jan 29, 2018 – The study will evaluate safety and efficacy of the Colovac bypass device for ostomy-free anastomosis protection following colorectal surgery SafeHeal, a leading innovator in the field of digestive surgery and developer of the Colovac device, announces today that it has enrolled the first five patients in its CE mark study. The Colovac device is a unique ...

BySafeHeal

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT